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Abstract
Background: The extent to which omega-3 fatty acid status is related to risk for death from any cause and for
incident cardiovascular disease (CVD) remains controversial. Objective: To examine these associations in the
Framingham Heart Study. Design: Prospective and observational. Setting: Framingham Heart Study
Offspring cohort. Measurements: The exposure marker was red blood cell levels of eicosapentaenoic and
docosahexaenoic acids (the Omega-3 Index) measured at baseline. Outcomes included mortality (total, CVD,
cancer, and other) and total CVD events in participants free of CVD at baseline. Follow-up was for a median
of 7.3 years. Cox proportional hazards models were adjusted for 18 variables (demographic, clinical status,
therapeutic, and CVD risk factors). Results: Among the 2500 participants (mean age 66 years, 54% women),
there were 350 deaths (58 from CVD, 146 from cancer, 128 from other known causes, and 18 from unknown
causes). There were 245 CVD events. In multivariable-adjusted analyses, a higher Omega-3 Index was
associated with significantly lower risks (P-values for trends across quintiles) for total mortality (P = .02), for
non-CVD and non-cancer mortality (P = .009), and for total CVD events (P = .008). Those in the highest
(>6.8%) compared to those in the lowest Omega-3 Index quintiles (<4.2%) had a 34% lower risk for death
from any cause and 39% lower risk for incident CVD. These associations were generally stronger for
docosahexaenoic acid than for eicosapentaenoic acid. When total cholesterol was compared with the
Omega-3 Index in the same models, the latter was significantly related with these outcomes, but the former
was not. Limitations: Relatively short follow-up time and one-time exposure assessment. Conclusions: A
higher Omega-3 Index was associated with reduced risk of both CVD and all-cause mortality.
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Abstract
BACKGROUND: The extent to which omega-3 fatty acid status is related to risk for death from 
any cause and for incident cardiovascular disease (CVD) remains controversial.
OBJECTIVE: To examine these associations in the Framingham Heart Study.
DESIGN: Prospective and observational.
SETTING: Framingham Heart Study Offspring cohort.
MEASUREMENTS: The exposure marker was red blood cell levels of eicosapentaenoic and 
docosahexaenoic acids (the Omega-3 Index) measured at baseline. Outcomes included mortality 
(total, CVD, cancer, and other) and total CVD events in participants free of CVD at baseline. 
Follow-up was for a median of 7.3 years. Cox proportional hazards models were adjusted for 18 
variables (demographic, clinical status, therapeutic, and CVD risk factors).
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RESULTS: Among the 2500 participants (mean age 66 years, 54% women), there were 350 
deaths (58 from CVD, 146 from cancer, 128 from other known causes, and 18 from unknown 
causes). There were 245 CVD events. In multivariable-adjusted analyses, a higher Omega-3 Index 
was associated with significantly lower risks (P-values for trends across quintiles) for total 
mortality (P = .02), for non-CVD and non-cancer mortality (P = .009), and for total CVD events (P 
= .008). Those in the highest (>6.8%) compared to those in the lowest Omega-3 Index quintiles 
(<4.2%) had a 34% lower risk for death from any cause and 39% lower risk for incident CVD. 
These associations were generally stronger for docosahexaenoic acid than for eicosapentaenoic 
acid. When total cholesterol was compared with the Omega-3 Index in the same models, the latter 
was significantly related with these outcomes, but the former was not.
LIMITATIONS: Relatively short follow-up time and one-time exposure assessment.
CONCLUSIONS: A higher Omega-3 Index was associated with reduced risk of both CVD and 
allcause mortality.
Keywords
Epidemiology; Prospective cohort study; Eicosapentaenoic acid; Docosahexaenoic acid; Omega-3 
fatty acids
Introduction
Several recent studies have linked higher blood levels and/or dietary intakes of the long-
chain n-3 polyunsaturated fatty acids (PUFAs) with greater longevity. Plasma phospholipid 
n-3 PUFA levels were inversely associated with total mortality rates in the Cardiovascular 
Health Study,1 and similar associations were seen for this endpoint with the red blood cell 
(RBC) content of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in the 
Heart and Soul Study.2 This latter metric, called for simplicity the Omega-3 Index, has been 
proposed as a risk factor for death from cardiovascular disease (CVD).3,4 Consistent with 
these observations, there is an inverse relationship between the Omega-3 Index and the rate 
of telomere attrition, a marker of cellular aging.5 Although early randomized controlled 
trials with n-3 PUFAs found reduced overall mortality,6,7 other more recent studies8–11 have 
not confirmed such a protective effect. Some of the potential reasons why recent studies may 
have yielded null results for intervention with n-3 PUFAs (background use of statins,12 short 
follow-up periods, low n-3 PUFA doses, improvements in acute care, etc.) have been 
reviewed.13,14 In the present investigation, we examined the relations between RBC n-3 
PUFA levels in participants in the Framingham Heart Study’s (FHS’s) Offspring cohort and 
total mortality as the primary endpoint, with secondary endpoints of death from CVD and 
other causes, and of incident coronary heart disease (CHD), CVD, and ischemic stroke.
Methods
The FHS is a longitudinal community-based cohort study that was initiated in 1948. Adult 
children of the original cohort were recruited in 1971 into the Framingham Offspring 
Cohort. The selection criteria for this cohort (and for the more racially diverse Framingham 
Omni Cohort) have previously been described.15,16 We evaluated Framingham Offspring/
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Omni participants (n = 3021) who attended their 8th/3rd examination cycles (2005–2008). 
Participants were excluded in hierarchical order if they were missing RBC FA measurements 
or relevant clinical covariates (n = 122), leaving 2899. We also excluded 399 with a history 
of CVD (ie, nonfatal CHD or stroke), leaving 2500 for the present investigation. The study 
protocol was approved by the Institutional Review Board of the Boston University Medical 
Center. Informed consent was provided by all participants.
Covariates and mortality outcomes
We considered 18 primary baseline demographic and CV risk covariates: sex, age, body 
mass index, marital status, education level, employment status, health insurance status, 
regular aspirin user, prevalent hypertensive status, use of cholesterol-lowering drugs, 
prevalent diabetes, history of CVD, alcohol consumption, smoking status, physical activity 
(in metabolic equivalent units), the total cholesterol to high-density lipoprotein cholesterol 
ratio, systolic blood pressure, and C-reactive protein. Four mortality endpoints were 
examined: total, CVD [fatal myocardial infarction (MI), CHD death, sudden cardiac death, 
fatal ischemic stroke, or other CVD death), cancer, and other (ie, non-CVD, non-cancer; 
Note that in the Framingham Heart Study, “other” causes of death were not specifically 
identified]. Incident CVD-related endpoints were also examined: total CVD (total stroke, 
total CHD, or CVD mortality), total stroke (any fatal or nonfatal ischemic stroke), and total 
CHD (fatal or nonfatal MI, CHD death or sudden cardiac death).
RBC FA analysis
Blood was drawn after a 10- to 12-hour fast into an EDTA tube, and RBCs were separated 
from plasma by centrifugation. The RBC fraction was frozen at −80°C immediately after 
collection. RBC FA composition was determined as described previously.17 Briefly, RBCs 
were incubated at 100°C using boron trifluoride methanol and hexane to generate FA methyl 
esters that were then analyzed by gas chromatography with flame ionization detection. N-3 
FAs analyzed included α-linolenic acid (ALA; 18:3n3), EPA (20:5n3), docosapentaenoic 
acid (DPA; 22:5n3), DHA (22:6n3), and the Omega-3 Index (EPA + DHA).3 The 
coefficients of variation for these were 10.7%, 7.8%, 3.8%, 3.3%, and 2.4%, respectively.
Statistical analysis
Sample characteristics were summarized using standard statistical metrics (eg, means, 
standard deviations (SDs), and correlations). Hazard ratios were estimated using the survival 
package in R.18 Primary analyses related incident clinical outcomes by date of event (or 
censoring) to quintiles of the Omega-3 Index, with follow-up analyses adjusting for 
demographic and medical history covariates. Secondary analyses explored relationships of 
outcomes by quintiles of individual n-3 PUFA levels, of a modified Omega-3 Index that 
included DPA, and by risk category of the Omega-3 Index (high risk, ≤4%; intermediate 
risk, >4% to <8%; and low risk, ≥8%).19 In other analyses, we included the n-6 FAs as 
covariates and also compared the n-6:n-3 ratio with the Omega-3 Index. Finally, baseline 
total cholesterol levels were compared with the Omega-3 Index in the same models to get a 
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sense of how this emerging risk factor compared with an established one. All analyses used 
2-sided tests at the P < .05 statistical significance level.
Results
Cohort description
This analysis was performed on 2500 Framingham Offspring study participants who were 
free of CVD at baseline and for whom FAs, clinical outcomes, and demographic covariates 
were available. Follow-up ended on December 31, 2016 (maximum, 11.2 years; median, 7.3 
years). Table 1 provides the baseline characteristics of the cohort by mortality status. The 
average age was 66 years, and there were more women (57%) than men (43%). There were 
350 deaths during the follow-up period: 58 were attributable to CVD (17%), 146 to cancer 
(42%), 128 to other known causes (37%), and 18 from unknown causes (5%). Overall, there 
were 245 incident cases of CVD, 119 of CHD, and 105 ischemic strokes. (Case and control 
numbers and length of follow-up for each outcome are in Table S1).
The Omega-3 Index and total and cause-specific mortality
We estimated the associations between adjusted risk for fatal outcomes across quintiles of 
the Omega-3 Index (Fig. 1, with details in Table S2). In the multivariable-adjusted model, 
death from any cause was significantly and inversely associated with the Omega-3 Index (P 
for trend = .02). When comparing individuals in the lowest quintile of the Omega-3 Index 
(<4.2%) to those in the highest (>6.8%), risk was 34% lower. Median values for the extreme 
quintiles were 3.7% and 7.8%. The modified Omega-3 Index (which included DPA) 
performed no differently from the original metric (Table S3), and an examination of the 
relations between risk and the three Omega-3 Index risk categories found a significant trend 
across the categories (P = .04), but only the intermediate category differed significantly from 
the high-risk category (possibly because there were 10-fold more subjects in the 
intermediate than the highest categories; Table S4). When we controlled for RBC n-6 PUFA 
levels in the original analysis, or substituted the n-6:n-3 ratio for the Omega-3 Index, there 
was no material improvement in mortality hazard ratios (Table S5). In neither case did the 
n-6 PUFAs alter the n-3 PUFA associations.
Regarding cause-specific mortality, the Omega-3 Index was only significantly associated 
with risk for death from “other” (non-CVD, non-cancer) causes (P for trend = .009), with the 
participants in the first (reference) quintile being at significantly higher risk than those in 
quintiles 2–5. There was a trend for reduced risk for CVD across Omega-3 Index levels (eg, 
there was a 61% lower risk between extreme quintiles), but with wide confidence intervals, 
the differences were nonsignificant. The results for total and cause-specific mortality were 
similar in analyses including all 2899 participants (ie, including those with a history of 
CVD; Table S6).
The Omega-3 Index and CVD outcomes
The Omega-3 Index was significantly and inversely associated with total CVD, total CHD, 
and total stroke after adjusting for covariates in a linear trend analysis across quintiles (Table 
2; P values for trends = .008, .03, and .006, respectively). Unadjusted hazard ratios are 
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shown in Table S7. The hazard ratio for total CVD was significantly reduced in quintile 5 vs 
1, but for total CHD or total stroke, no individual quintile differed significantly from the 
reference. Similar findings were observed in the full cohort (n = 2899) for total CHD and 
total stroke, but the relationship with total CVD was no longer statistically significant (Table 
S8). Using the modified Omega-3 Index (with DPA) did not change the pattern of results 
(Table S3), and when Omega-3 risk categories were tested, the general pattern of 
relationships remained the same, but they were mostly nonsignificant (Table S4). Finally, 
neither including n-6 PUFAs as covariates nor replacing the Omega-3 Index with the n-6:n-3 
ratio altered the original results (Table S5).
Individual RBC n-3 PUFAs and outcomes
The adjusted risk for experiencing the endpoints of interest by each of the four n-3 PUFAs 
separately is shown in Table 3 (unadjusted hazard ratios in Table S9). The plant-derived n-3 
PUFA, ALA, was not significantly associated with reduced risk for any of the outcomes 
tested (Table 3). In general, as the levels of the EPA and (especially) DHA increased, risk for 
disease outcomes and total (and other) mortality decreased (Table 3). The only outcome that 
DPA was (marginally, P = .059) associated with was death from other causes (Table 3).
Omega-3 Index vs total cholesterol
In the head-to-head comparison of the Omega-3 Index and total cholesterol for total and 
CVD mortality and for the 3 CVD outcomes, the former metric was significantly associated 
with risk for 4 of the 5 outcomes, whereas the total cholesterol level, in the same models, 
was not associated with risk for any of these outcomes (Table 4).
Discussion
In this study of participants in the Framingham Offspring study, the baseline Omega-3 Index 
at about 66 years of age was inversely associated with total mortality over the next 7 years—
with values of the Omega-3 Index significantly lower in those who died during follow-up 
than those who did not. The same was generally true for the 2 components of the Index, EPA 
and DHA, but not for RBC DPA n-3 or ALA. Findings for the Omega-3 Index persisted in a 
model adjusted for 18 other relevant variables including plasma lipids and C-reactive 
protein.
We recently reported similar findings to these in the Women’s Health Initiative Memory 
Study where there was a significant inverse trend across quartiles of the Omega-3 Index for 
total mortality, with the highest quartile being at 22% lower risk for death compared with the 
lowest.20 That study followed a nationwide sample of 6500, approximately 70-year-old 
women for 15 years. Kleber et al. also found a 9% decrease in risk for all-cause mortality 
per 1 SD increase in the Omega-3 Index after 10 years of follow-up in 3259 German CHD 
patients.21 In the present study, we followed up 2500 men and women for half as long and 
found an interquintile risk reduction of 34%. We also found reduced risk for total CVD 
events, CHD events, and stroke. The approximately 50% lower risk for CVD mortality was, 
however, not statistically significant, most likely due to having only 58 events in the analysis 
(see below). Nevertheless, these findings are generally consistent with those of several meta-
analyses that all linked higher n-3 PUFA biomarker levels with reduced risk for “coronary 
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events”22 or fatal CHD.19,23 This study was somewhat unique, however, in exploring 
relations between RBC n-3 PUFA levels instead of whole plasma or plasma phospholipid 
n-3 PUFAs. But since these markers of n-3 PUFA status are strongly intercorrelated,24 this 
coherence is expected.
The causes of death most strongly associated with the Omega-3 Index were non-CVD and 
non-cancer, ie, “other” causes. By design, the FHS focused primarily on CVD outcomes, so 
details of the other causes of death are unavailable. An 11% reduction (per 1 SD increase in 
the Omega-3 Index) in risk for death from other causes was also seen in the women’s study 
mentioned previously.20 It is unclear what mechanism might explain this observation; but 
since n-3 PUFAs are known to have a wide variety of effects on cell membrane biology,25,26 
a systemic impact of higher levels of these FAs on overall cellular health is possible. As 
noted earlier, several recent randomized trials of fish oil with total mortality as an endpoint 
have been null, but they typically showed trends toward a benefit.27,28 More consistent with 
our observations was a 2017 meta-analysis,29 which found a significant 19% reduction in 
risk for coronary death associated with fish oil treatment. Two nonrandomized retrospective 
studies using governmental databases to track patient outcomes (one from England30 and 
another from Italy31) reported lower risk for all-cause mortality in those CHD patients who 
had been prescribed 1 g of fish oil at discharge. Finally, higher plasma long-chain n-3 FA 
levels were strongly associated with reduced risk for total mortality and CHD outcomes in 
renal transplant patients in Norway.32
A somewhat surprising observation in this study was the low rate of CVD in this population, 
with only 17% of deaths being attributable to CVD (as opposed to 42% from cancer). Part of 
this is clearly the exclusion from the analysis set of participants with CVD at baseline, but 
even including these individuals, the CVD death rate was only 22%. This relatively low 
CVD death rate should perhaps not be surprising given the reduction in heart disease 
mortality in the United States over the last several decades. For example, the age-
standardized death rate from heart disease per 100,000 people dropped from 520 in 1969 to 
167 in 2014, a 68% decline.33
With regard to the individual RBC n-3 PUFAs studied here, in the multivariable-adjusted 
model, ALA was not significantly related to any measured outcome in the quintile analysis. 
The null mortality findings for ALA agree with some previous studies,34,35 but higher 
circulating ALA levels (primarily plasma and plasma phospholipids) have been favorably 
associated with CVD death,23 and ALA intake was associated with reduced total mortality 
in a large randomized clinical trial (RCT) from Spain.36 So, evidence for ALA remains 
mixed. Turning to DPA, in the final model, it was not related with any examined outcome 
(although trends were favorable). This contrasts with a previous meta-analysis in which this 
FA (again, more often measured in whole plasma or plasma phospholipids) was inversely 
associated with risk for CVD death.23 In light of this and other prior reports (eg, in heart 
failure37), the utility of RBC DPA as a risk marker remains unclear. Nevertheless, because of 
the growing evidence for a beneficial role of DPA,38 it is reasonable to ask why this FA is 
not a component of the Omega-3 Index. Including it would be reasonable if adding it to EPA 
and DHA improved the utility of the metric in risk assessment. In the present study, we 
compared the original and the modified Omega-3 Index (Table S3) and found essentially the 
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same associations with outcomes for both. This would be expected since the correlation 
between these 2 predictor variables is 0.98. Hence, our findings provide no compelling 
reason to alter the original definition/components of the Omega-3 Index.
We found that the risk of stroke was inversely associated with the Omega-3 Index, but not in 
a linear manner, ie, hazard ratios were reduced only in the upper 2 quintiles; however, the 
trend across quintiles was significant. Risk reduction was largely associated with DHA, 
where risk was 59% lower in the fifth (vs the first) quintile (P < .05). An association 
between serum long-chain n-3 PUFA levels and stroke risk has been reported previously in 
cross-sectional studies.39,40 The impact of marine n-3 PUFA levels on ischemic stroke may 
extend beyond the risk of incident event. Lower plasma proportions of EPA and DHA have 
been shown to be independently associated with increased ischemic stroke severity and, for 
DHA, poor functional outcomes at 90 days after stroke.41 In addition, a higher ratio of EPA 
or DHA to arachidonic acid in serum was associated with lower likelihood of early 
neurologic deterioration after ischemic stroke.42 A 2012 meta-analysis of 32 observational 
cohorts and 13 n-3 RCTs reported inverse associations with stroke and fish intake, but no 
significant relations with either circulating biomarkers or with supplementation,43 although a 
2017 study of plasma phospholipid omega-3 FA and incident stroke from 3 cohorts found 
inverse relations with DHA as we did here.44 A randomized, open-label study in patients 
surviving myocardial infarction45 showed a reduction in risk of nonfatal stroke with n-3 FA 
supplementation, and an open-label study in Japan demonstrated no effect on primary 
prevention of stroke but a 20% relative reduction in recurrent total stroke with EPA 
supplementation.46 However, some studies have found no relations between n-3 PUFA levels 
and stroke,47,48 so the n-3 PUFA and stroke literature is mixed, and more studies are needed.
A variety of exploratory analyses were conducted here. Given the controversies regarding 
the CVD effects of the n-6 PUFAs and the frequent use of the n-6:n-3 ratio, in one analysis 
we controlled for RBC n-6 PUFA levels and in another we directly compared the ratio with 
the Omega-3 Index. In neither case did the n-6 PUFAs add or detract from the omega-3 
effect. Hence, this study found no support for using a combined metric with n-6 and n-3 
PUFAs. Finally, we compared associations with disease outcomes for the Omega-3 Index 
with that of total cholesterol, one of the most well-known CVD risk factors. This analysis 
was undertaken to give some perspective of the relative sensitivity of these 2 biomarkers. In 
head-to-head comparisons with the same multivariable models, a higher Omega-3 Index was 
significantly associated with reduced risk for 4 of the 5 outcomes studies, but cholesterol 
was unrelated to risk for any outcome. This may be because about 38% of participants were 
on a cholesterol-lowering medication, and so cholesterol levels at baseline were 
therapeutically reduced; because 399 subjects with a diagnosis of CVD at baseline were 
excluded; or because those who were particularly susceptible to cholesterol-induced CHD 
may have already died. There is indeed some controversy regarding the predictive power of 
serum cholesterol in older individuals.49 Nevertheless, in the unique context of this study in 
which we controlled for 17 other variables, cholesterol levels were unassociated with these 
outcomes. Whatever the reasons, this observation supports the need for further research to 
more clearly define the relative roles of traditional and emerging biomarkers in risk 
stratification.
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The originally proposed (in 2004) clinical cut-points for the Omega-3 Index were <4% (high 
risk) and >8% (low risk).3 Although these have recently been confirmed in a meta-analysis 
including 10 cohorts and over 27,000 subjects,19 it was of interest to explore their utility in 
the present study as well. We found a significant trend across risk categories for total 
mortality and significant reductions in risk for the intermediate group compared with the 
high group, but not for the >8% category. This may reflect a nonlinear relationship between 
the Omega-3 Index and risk as has been suggested by others,25 or the fact that only 10% of 
the sample was in the >08% category. Nevertheless, the hazard ratio of 0.69 for any death in 
the >8% category is at least suggestive of lower risk.
As alluded to earlier, mechanisms that may explain the associations between higher RBC 
n-3 PUFA and improved longevity and reduced CVD risk are not clearly understood, but 
there are beneficial effects of these FAs on a variety of CV risk factors. These include 
reductions in serum triglyceride levels,50 blood pressure,51 platelet aggregation,52 heart rate,
53
 susceptibility to ventricular fibrillation (in some settings),54 inflammatory markers,55,56 
and plaque vulnerability57,58 along with improvements in endothelial function.59 The 
observation that blood EPA + DHA levels are independently associated with slower rates of 
telomere shortening,5 a purported marker of “cellular aging,” is yet another favorable 
biomarker relationship, but it is not a molecular mechanism.
From an observational study, we cannot conclude that raising the Omega-3 Index will have 
heart benefits and/or prolong life. Nevertheless, it is instructive to consider how much more 
EPA + DHA an individual might need to consume to move the median Omega-3 Index in 
quintile 1 (3.7%) to that in quintile 5 (7.8%). Based on a recent dose-response study,60 one 
can estimate that it would take about 1300 more mg of EPA + DHA per day to do this. This 
amount of EPA + DHA could be obtained from a single serving (100 g) of farmed salmon61 
daily. Alternatively, 4 standard fish oil pills per day would suffice. Several early omega-3 
RCTs used 800–1000 mg/d and reported reduced total mortality,6,7,62 whereas other more 
recent studies at the same dose have not.9,11,63 Several possible reasons for this discrepancy 
have been proposed.64,65
Strengths and limitations
The strengths of our investigation include the relatively large sample size from a well-
characterized community, the unambiguous nature of the primary endpoint, and the use of an 
objective and standardized biomarker of PUFA exposure that has low biological variability.
66
 Weaknesses include the assessment of PUFA exposure at only one point in time (which 
cannot capture changes in PUFA status that may have occurred during follow-up) and the 
largely Caucasian cohort (which precludes firm conclusions regarding other races). Also, the 
relatively low event rates, especially for CVD death, limited our ability to detect associations 
with this endpoint. Although clearly affected by omega-3 PUFA intake, other factors can 
influence the Omega-3 Index such as smoking and body weight,67 both of which were 
controlled for here. What we did not (and could not) control for is heritability, which we 
showed previously to explain about 24% of the variability in this biomarker.67 In the same 
vein, we did not include in our models the intake of key nutrients (kilocalories, saturated 
FAs, salt, fiber, etc.), which might contribute to the relationships reported here. However, by 
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controlling for some of the physiological/metabolic consequences of consuming diets of 
poor quality (body weight, blood pressure, hyperlipidemia, and CRP levels), as well as for 
socioeconomic variables (which themselves track with poor diets), it is unlikely that 
including individual nutrients would have altered the outcome of the study. As always, the 
presence of residual or unmeasured confounding also precludes inferences about causality. 
For example, despite controlling for multiple lifestyle/health factors, higher omega-3 PUFA 
levels may simply be a marker for a healthier overall diet and behaviors, which themselves, 
independent of the omega-3 levels, may be cardioprotective.
In conclusion, we observed that higher RBC levels of n-3 PUFAs were associated with 
greater longevity and reduced risk for several CVD-related endpoints in this community-
based sample. These findings, in the context of the totality of available evidence on this 
topic, provide further support for a role for the use of the Omega-3 Index in risk 
stratification algorithms.
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APPENDIX
Table S1
Distribution of outcomes (n = 2500)
Number of people
with events (cases)
Number of people
without events
(controls)
Median follow-up
days*
Maximum follow-up
days*
Total CVD 245 2255 2351 3833
Total CHD 119 2381 2342 3815
Ischemic stroke 105 2395 2342 3833
CVD mortality 58 2442 2673 3815
Death from any cause† 350 2150 2686 3815
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*
Days to event or days to censoring.
†
The causes of the 350 observed deaths, besides CVD, were 146 cancer (42%), 128 other (37%), and 18 unknown (5%).
Table S2
Risk of fatal events by Omega-3 Index (n = 2500)
Hazard ratios (95% CIs)
CVD mortality Cancer mortality Other mortality Any mortality
Omega-3 Index–unadjusted
 <4.2% (n = 508) 1.0 1.0 1.0 1.0
 4.2%–4.9% (n = 500) 0.97 (0.41, 2.30) 0.94 (0.58, 1.55) 0.59 (0.34, 1.02) 0.81 (0.59, 1.12)
 4.9%–5.7% (n = 501) 0.96 (0.43, 2.16) 0.88 (0.50, 1.57) 0.63 (0.36, 1.09) 0.78 (0.56, 1.10)
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Hazard ratios (95% CIs)
CVD mortality Cancer mortality Other mortality Any mortality
 5.7%–6.8% (n = 502) 1.10 (0.46, 2.62) 0.72 (0.42, 1.23) 0.67 (0.40, 1.11) 0.73 (0.53, 1.02)
 >6.8% (n = 489) 0.88 (0.39, 2.01) 1.19 (0.72, 1.97) 0.53 (0.31, 0.91) * 0.81 (0.58, 1.12)
 P-value for linear trend .86 .85 .07 .16
Omega-3 Index–adjusted§
 <4.2% (n = 508) 1.0 1.0 1.0 1.0
 4.2%–4.9% (n = 500) 0.57 (0.23, 1.40) 0.66 (0.38, 1.14) 0.54 (0.31, 0.94) * 0.74 (0.53, 1.04)
 4.9%–5.7% (n = 501) 0.54 (0.20, 1.47) 0.73 (0.42, 1.28) 0.38 (0.20, 0.73) † 0.67 (0.46, 0.96) *
 5.7%–6.8% (n = 502) 0.56 (0.22, 1.43) 0.60 (0.35, 1.03) 0.44 (0.25, 0.79) † 0.59 (0.41, 0.86) †
 >6.8% (n = 489) 0.39 (0.15, 1.02) 0.96 (0.56, 1.64) 0.44 (0.24, 0.79) † 0.66 (0.45, 0.96) *
 P-value for linear trend .10 .88 .009 † .02 *
CVD, cardiovascular disease; CI, confidence interval.
*
P < .05
†P < .01
‡P < .001.
All significant hazard ratios/P-values are shown in bold italics.
§Adjusted for all variables in Table 1 except baseline CVD.
Table S3
Risk of events by Omega-3 Index modified to include 
docosapentaenoic acid (n = 2500)
Hazard ratios (95% CIs
Total CVD Total CHD Total stroke Any mortality
Omega-3 Index–adjusted
 <4.2% (n = 508) 1.0 1.0 1.0 1.0
 4.2%–4.9% (n = 500) 1.06 (0.69, 1.63) 1.05 (0.60, 1.83) 1.16 (0.60, 2.24) 0.74 (0.53, 1.04)
 4.9%–5.7% (n = 501) 1.10 (0.72, 1.68) 0.81 (0.44, 1.48) 1.30 (0.68, 2.49) 0.67 (0.46, 0.96) *
 5.7%–6.8% (n = 502) 0.74 (0.47, 1.17) 0.63 (0.34, 1.20) 0.59 (0.28, 1.25) 0.59 (0.41, 0.86) †
 >6.8% (n = 489) 0.61 (0.37, 0.99) * 0.58 (0.29, 1.18) 0.45 (0.20, 1.03) 0.66 (0.45, 0.96) *
 P-value for linear trend .008 † .03 * .006 † .02 *
Modified Omega-3 Index (+DPA)–
adjusted
 <6.7% (n = 510) 1.0 1.0 1.0 1.0
 6.7%–7.5% (n = 497) 1.01 (0.66, 1.54) 0.93 (0.54, 1.61) 1.04 (0.52, 2.07) 0.75 (0.53, 1.06)
 7.5%–8.4% (n = 502) 0.83 (0.54, 1.27) 0.58 (0.32, 1.05) 1.09 (0.57, 2.08) 0.48 (0.40, 0.84) †
 8.4%–9.7% (n = 507) 0.69 (0.44, 1.08) 0.54 (0.29, 1.01) 0.65 (0.31, 1.35) 0.72 (0.50, 1.04)
 >9.7% (n = 484) 0.64 (0.40, 1.03) 0.54 (0.27, 1.05) 0.51 (0.23, 1.14) 0.61 (0.41, 0.90) *
 P-value for linear trend .012 * .013 * .024 * .02 *
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01
‡P < .001.
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All significant hazard ratios/P-values are shown in bold italics.
Adjusted for all variables in Table 1.
Table S4
Risk of events by Omega-3 Index risk categories (n = 
2500)
Hazard ratios (95% CIs)
Total CVD Total CHD Total stroke Any mortality
Omega-3 Index–unadjusted
 <4% (n = 416) 1.0 1.0 1.0 1.0
 4%–8% (n = 1876) 1.03 (0.72, 1.48) 0.94 (0.57, 1.54) 1.12 (0.64, 1.94) 0.73 (0.56, 0.96) *
 >8% (n = 208) 0.77 (0.43, 1.38) 0.73 (0.34, 1.58) 0.88 (0.33, 2.32) 0.85 (0.68, 1.07)
 P-value for linear trend .45 .48 .93 .15
Omega-3 Index–adjusted§
 <4% (n = 416) 1.0 1.0 1.0 1.0
 4%–8% (n = 1876) 0.88 (0.59, 1.32) 0.85 (0.49, 1.47) 0.91 (0.48, 1.71) 0.61 (0.45, 0.83) †
 >8% (n = 208) 0.68 (0.36, 1.27) 0.83 (0.35, 1.94) 0.50 (0.17, 1.52) 0.69 (0.43, 1.13)
 P-value for linear trend .59 .23 .21 .04 *
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01
‡P < .001.
All significant hazard ratios/P-values are shown in bold italics.
§Adjusted for all variables in Table 1.
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Table S6
Risk of fatal events by Omega-3 Index (n = 2899)
Hazard ratios (95% CIs)
Cancer mortality Other mortality CVD mortality Any mortality
Omega-3 Index–unadjusted
 <4.2% (n = 580) 1.0 1.0 1.0 1.0
 4.2%–4.9% (n = 579) 0.88 (0.58, 1.33) 0.66 (0.41, 1.07) 0.84 (0.44, 1.61) 0.83 (0.63, 1.09)
 4.9%–5.7% (n = 580) 0.86 (0.53, 1.38) 0.62 (0.39, 1.01) 0.93 (0.50, 1.73) 0.78 (0.58, 1.04)
 5.7%–6.8% (n = 580) 0.61 (0.37, 1.00) 0.65 (0.41, 1.03) 1.06 (0.56, 2.00) 0.72 (0.54, 0.96) *
 >6.8% (n = 480) 0.97 (0.62, 1.51) 0.58 (0.37, 0.92) * 0.92 (0.51, 1.68) 0.79 (0.60, 1.04)
 P-value for linear trend .51 .046 * .96 .05
Omega-3 Index–adjusted
 <4.2% (n = 580) 1.0 1.0 1.0 1.0
 4.2%–4.9% (n = 579) 0.70 (0.43, 1.12) 0.65 (0.41, 1.03) 0.57 (0.23, 1.42) 0.79 (0.59, 1.06)
 4.9%–5.7% (n = 580) 0.75 (0.46, 1.21) 0.38 (0.22, 0.67) ‡ 0.90 (0.45, 1.76) 0.70 (0.52, 0.95) *
 5.7%–6.8% (n = 580) 0.55 (0.33, 0.91) * 0.52 (0.31, 0.87) * 0.88 (0.42, 1.85) 0.66 (0.49, 0.90) †
 >6.8% (n = 480) 0.87 (0.55, 1.39) 0.49 (0.29, 0.84) † 0.74 (0.36, 1.50) 0.71 (0.52, 0.97) *
 P-value for linear trend .45 .01 * .87 .02 *
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01
‡P < .001.
All significant hazard ratios/P-values are shown in bold italics.
Adjusted for all variables in Table 1 except baseline CVD.
Table S7
Unadjusted risk of events by Omega-3 Index (n = 2500)
Hazard ratios (95% CIs)
Total CVD Total CHD Total stroke
Omega-3 Index–unadjusted
 <4.2% (n = 508) 1.0 1.0 1.0
 4.2%–4.9% (n = 500) 1.08 (0.72, 1.63) 1.07 (0.63, 1.82) 1.19 (0.65, 2.20)
 4.9%–5.7% (n = 501) 1.33 (0.90, 1.96) 0.88 (0.50, 1.53) 1.64 (0.92, 2.93)
 5.7%–6.8% (n = 502) 0.88 (0.57, 1.34) 0.73 (0.41, 1.33) 0.77 (0.39, 1.53)
 >6.8% (n = 489) 0.70 (0.45, 1.10) 0.59 (0.32, 1.07) 0.68 (0.32, 1.45)
 P-value for linear trend .07 .03 * .16
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01
‡P < .001.
All significant hazard ratios/P-values are shown in bold italics.
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Table S8
Risk of CVD-related events by Omega-3 Index (n = 
2899)
Hazard ratios (95% CIs)
Total CVD Total CHD Total stroke
Omega-3 Index–unadjusted
 <4.2% (n = 580) 1.0 1.0 1.0
 4.2%–4.9% (n = 579) 1.07 (0.76, 1.52) 0.81 (0.51, 1.28) 1.53 (0.88, 2.66)
 4.9%–5.7% (n = 580) 1.24 (0.89, 1.73) 0.74 (0.47, 1.18) 1.77 (1.03, 3.02) *
 5.7%–6.8% (n = 580) 0.99 (0.70, 1.41) 0.80 (0.51, 1.27) 1.20 (0.67, 2.14)
 >6.8% (n = 580) 0.88 (0.62, 1.26) 0.65 (0.41, 1.04) 1.19 (0.65, 2.20)
 P-value for linear trend .40 .10 .92
Omega-3 Index–adjusted§
 <4.2% (n = 580) 1.0 1.0 1.0ǁ
 4.2%–4.9% (n = 579) 1.11 (0.74, 1.67) 1.08 (0.67, 1.74) 1.36 (0.77, 2.45)
 4.9%–5.7% (n = 580) 1.31 (0.90, 1.93) 0.85 (0.50, 1.44) 1.20 (0.63, 2.28)
 5.7%–6.8% (n = 580) 1.00 (0.68, 1.46) 0.73 (0.46, 1.17) 0.76 (0.41, 1.40)
 >6.8% (n = 580) 0.82 (0.54, 1.25) 0.56 (0.32, 0.99) * 0.51 (0.26, 1.02)
 P-value for linear trend .25 .01 * .003
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01
‡P < .001.
All significant hazard ratios/P-values are shown in bold it.
§Adjusted for all variables in Table 1.
ǁ
The highest quintile of the Omega-3 Index had significantly lower risk for total stroke than the second quintile [0.32 (0.15, 
0.68)†] and the third quintile [0.38 (0.19, 0.74)†] after adjusted for all variables in Table 1.
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Figure 1. 
Relations between quintiles of the Omega-3 Index and hazard ratios (+95% confidence 
interval) for death from CVD (n = 58), cancer (n = 146), other causes (n = 128), and all 
causes (n = 350, including 18 of unknown causes). Data are from 2500 participants free of 
baseline CVD followed for a median of 7.3 years. Adjusted for all variables in Table 1. P-
values for trend are shown above the columns. CVD, cardiovascular disease; CHD, coronary 
heart disease.
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Table 1
Demographic overview (n = 2500)
Died (n = 350) Still living (n = 2150) Total
Variable % (n) or mean (SD)
Sex
 Male 52.9% (185) 41.5% (893) 43.1% (1078)
 Female 47.1% (165) 58.5% (1257) 56.9% (1422)
Age  72.9 (8.6)  64.4 (8.2)  65.56 (8.76)
BMI  27.9 (5.9)  28.3 (5.4)  28.2 (5.4)
Marital status
 Single/never married  4.3% (15)  6.7% (144)  6.4% (159)
 Married 63.7% (223) 70.7% (1519) 69.7% (1742)
 Separated/divorced 12.0% (42) 12.7% (273) 12.6% (315)
 Widowed 18.3% (64) 9.4% (203) 10.7% (267)
Education
 Some high school or less  6.0% (21)  2.4% (51)  2.9% (72)
 High school graduate 33.7% (118) 24.8% (533) 26.0% (651)
 Some college or vocational 22.9% (78) 21.9% (471) 22.0% (549)
 College graduate 36.6% (128) 50.5% (1086) 48.6% (1214)
Employment
 Employed 31.1% (109) 56.3% (1210) 52.8% (1319)
 Disabled/unemployed  3.1% (11)  2.5% (53)  2.6% (64)
 Retired 64.3% (225) 40.8% (877) 44.1% (1102)
Health insurance status
 No insurance  2.3% (8)  1.9% (40)  1.9% (48)
 Insurance, but no prescription 11.4% (40) 8.4% (181) 8.8% (221)
 Full insurance 84.0% (294) 88.7% (1906) 88.0% (2200)
Regular aspirin use 49.7% (174) 38.6% (830) 40.2% (1004)
Prevalent hypertension 57.1% (200) 42.2% (908) 44.3% (1108)
Cholesterol medication 41.4% (145) 36.9% (794) 37.6% (939)
Prevalent diabetes 22.3% (78) 11.6% (249) 13.1% (327)
Alcohol consumption
 None 34.0% (119) 23.2% (499) 24.7% (618)
 <1 drink per day 36.0% (126) 50.7% (1089) 48.6% (1215)
 1–2 drinks per day 22.6% (79) 20.2% (434) 20.5% (513)
 >2 drinks per day  6.9% (24)  5.7% (123)  5.9% (147)
Smoking
 Not current smoker 89.1% (312) 90.5% (1946) 90.3% (2258)
 Current 10.6% (37) 9.3% (200) 9.5% (237)
METS  4.7 (15.4)  3.3 (8.6)  3.5 (9.9)
Total to HDL cholesterol ratio  3.5 (1.1)  3.5 (1.0)  3.5 (1.1)
Systolic BP 133.6 (19.8) 128.2 (16.9) 129.0 (17.4)
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Died (n = 350) Still living (n = 2150) Total
Variable % (n) or mean (SD)
C-reactive protein  4.9 (12.7)  3.0 (6.1)  3.3 (7.4)
BMI, body mass index; METS, metabolic equivalents; HDL, high-density lipoprotein; BP, blood pressure.
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Table 2
Adjusted risk of events by Omega-3 Index (n = 2500)§
Hazard ratios (95% CIs)
Total CVD Total CHD Total stroke
Omega-3 Index
 <4.2% (n = 508) 1.0 1.0 1.0
 4.2%–4.9% (n = 500) 1.06 (0.69, 1.63) 1.05 (0.60, 1.83) 1.16 (0.60, 2.24)
 4.9%–5.7% (n = 501) 1.10 (0.72, 1.68) 0.81 (0.44, 1.48) 1.30 (0.68, 2.49)
 5.7%–6.8% (n = 502) 0.74 (0.47, 1.17) 0.63 (0.34, 1.20) 0.59 (0.28, 1.25)
 >6.8% (n = 489) 0.61 (0.37, 0.99) * 0.58 (0.29, 1.18) 0.45 (0.20, 1.03)
 P-value for linear trend
.008 † .03 * .006 †
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01.
All significant hazard ratios/P-values are shown in bold italics.
§Adjusted for all variables in Table 1 except baseline CVD.
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Table 4
Omega-3 Index and total cholesterol: Associations with risk for disease outcomes (n = 
2500)
Hazard ratios (95% CIs)
Biomarker Total CVD Total CHD Total Stroke CVD mortality Any Mortality
Omega-3 Index§
 <4.2% (n = 506) 1.0 1.0 1.0 1.0 1.0
 4.2%–4.9% (n = 500) 1.08 (0.70, 1.65) 1.06 (0.61, 1.85) 1.20 (0.63, 2.27) 0.65 (0.27, 1.54) 0.74 (0.53, 1.03)
 4.9%–5.7% (n = 500) 1.11 (0.73, 1.68) 0.81 (0.44, 1.47) 1.32 (0.69, 2.50) 0.53 (0.19, 1.49) 0.67 (0.47, 0.97)
 5.7%–6.8% (n = 502) 0.74 (0.47, 1.17) 0.63 (0.34, 1.19) 0.61 (0.29, 1.27) 0.58 (0.22, 1.55) 0.58 (0.41, 0.84) †
 >6.8% (n = 489) 0.63 (0.39, 1.01) 0.59 (0.30, 1.17) 0.47 (0.21, 1.06) 0.44 (0.16, 1.91) 0.65 (0.45, 0.94)
 P-value from linear trend testǁ .009 † .03 * .006 † .19 .01 *
Total cholesterol
§
 <154 (n = 406) 1.0 1.00 1.0 1.0 1.0
 154–175 (n = 491) 1.03 (0.69, 1.56) 1.02 (0.55, 1.89) 0.88 (0.47, 1.66) 1.22 (0.53, 2.77) 0.73 (0.50, 1.05)
 176–194 (n = 520) 0.95 (0.62, 1.45) 1.29 (0.71, 2.37) 0.63 (0.31, 1.27) 0.67 (0.26, 1.77) 0.72 (0.49, 1.06)
 195–218 (n = 551) 0.89 (0.56, 1.39) 1.01 (0.53, 1.92) 0.69 (0.32, 1.40) 1.07 (0.30, 3.79) 0.91 (0.64, 1.31)
 >218 (n = 530) 1.09 (0.66, 1.80) 1.59 (0.81, 3.11) 0.89 (0.41, 1.93) 0.31 (0.72, 1.34) 0.96 (0.66, 1.40)
 P-value from linear trend testǁ .99 .26 .50 .27 .11
CVD, cardiovascular disease; CHD, coronary heart disease; CI, confidence interval.
*P < .05
†P < .01
All significant hazard ratios/P-values are shown in bold italics.
§
Hazard ratios presented here were adjusted for all variables in Table 1 with the addition of grouped total cholesterol (and removing total 
cholesterol to high-density lipoprotein cholesterol ratio) and the grouped Omega-3 Index.
ǁ
Linear trend test models were fit for both the Omega-3 Index and TC simultaneously, after adjusting for variables as described in footnote “§”.
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